ClinicalTrials.gg
RecruitingNCT06726928RESOLVEUpdated Sep 4, 2025

SiREX-Stent for the Treatment of SymptOmatic Lateral VEnous Sinus Stenosis

An interventional study of Sinus Stenting in Treatment of Symptomatic Lateral Sinus Stenosis and Treatment of Pulsatile Tinnitus Due tu Sinus Stenosis, sponsored by Acandis GmbH. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Acandis GmbH · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Tinnitus with a site in France — 11 open to participants now, 11 under way, none of them phase 3. Tinnitus · France.

Planned enrollment
12th of 24
78 · median 71
Started
2025
with 2 others
No phase
19 of 29
10 open now
Primary completion
2027-01
later than 2 of 10 live
Registered
24th of 29
by date
Lead sponsor
1 of 29
Acandis GmbH

Among the 29 studies in Tinnitus with a site in France, this one is the 12th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 19 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 24th registered.

Tinnitus

446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

Browse Tinnitus studies →

Open to participants now

11 of the 29 studies in Tinnitus with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Tinnitus with a site in France, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy, safety and the clinical benefit of the SiREX stent for the treatment of disabling pulsatile tinnitus due to stenosis of lateral sinus.

The study will enrol patients suffering from pulsatile tinnitus related to a lateral sinus stenosis lasting more than three months, and who want to be treated with lateral sinus stenting

Read the detailed description

As there is currently no specifically developed and approved stent on the market for the treatment of symptomatic sinus stenosis, stenting has so far been performed with stents intended for carotid stenosis or peripheral treatment, which leads to considerable limitations. Because of stiff delivery systems (6F or bigger) progression inside the venous sinus is sometimes difficult. Furthermore, the length of such devices is often insufficient to cover the entire pathological segment and more than one device needs to be implanted in an overlaying manor (telescoping), which is accompanied with higher complication risks.

The objective of the study is to prove the efficacy and clinical safety of the new dedicated SiREX Stent with optimized technical features (smaller delivery system, longer lengths, reduced radial force), specially developed for the treatment of venous sinus stenosis. Pulsatile tinnitus is expected to disappear immediately after treatment with a stable effect during time.

03

Conditions studied

  • Treatment of Symptomatic Lateral Sinus Stenosis
  • Treatment of Pulsatile Tinnitus Due tu Sinus Stenosis

Browse trials for

Keywords

  • Pulsatile Tinnitus
  • Sinus vein stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Patient ≥ 18 years old

      • Disabling pulsatile tinnitus lasting for more than three months
      • Venous type: pulsatile tinnitus is interrupted by ipsilateral jugular vein compression
      • Lateral sinus stenosis visible on venous MRA or venous angio CT
      • Exclusion of other cause (excepted dehiscence of the lateral sinus related to the stenosis) of PT on MRI and on the temporal bone CT
      • Stenosis located on a dominant or codominant lateral sinus
      • Stenosis associated with a venous gradient of at least 3 mm Hg under general anesthesia (GA) in the absence of sinus dehiscence, or 2 mm Hg under GA if there is sinus dehiscence in a mastoid cell
      • Patients asking for the treatment of her/his pulsatile tinnitus
      • Patients accepting to receive the SiREX® Stent (instead of a carotid stent)
      • Written

Exclusion criteria

Exclusion Criteria:

  • Non-pulsatile tinnitus or pulsatile tinnitus unrelated to lateral sinus stenosis
  • Stenosis with gradient \< 2 mm Hg in the absence of associated lateral sinus dehiscence
  • Any for treatment according to Instructions for Use:

    • Patients in whom the size of the venous vessel section to be treated does not lie within the range indicated for the stent.
    • Patients for whom angiography shows that the anatomic morphology is not suitable for endovascular treatment due to severe vessel tortuosity or stenosis.Patients who were not pre-treated with antiplatelet agents prior to the procedure.
    • Patients in whom treatment with antiplatelet agents and/or anticoagulants is contraindicated.
    • Patients with an acute subarachnoid haemorrhage.
    • Patients with an active bacterial infection.
    • Patients who are hypersensitive to nickel-titanium.
  • Pregnant or breastfeeding woman
  • Subject is participating in another clinical study
  • Patients with a life-threatening event in the last 6 months
  • Patients with a under 12 months
  • Known, severe comorbidities, which will likely influence carrying out of the follow-up visits (cancer, alcohol/drug abuse or dementia)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Other
    Intervention

    Novel medical device

    Device: Sinus Stenting

Interventions

  • DeviceSinus Stenting

    Stenting of symptomatic sinus stenosis

06

What researchers measure

Primary outcomes

  1. Disappearance of pulsatile tinnitus at 90 (± 20) days

    Disappearance of pulsatile tinnitus at 90 (± 20) days after resolving of the lateral sinus stenosis with SiREX Stent

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jan 2027, 16 months later.

Of 153 interventional studies with no phase under Tinnitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 16 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartEst.
Sep 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2029
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06726928
Lead sponsor
Acandis GmbH
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Sep 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 4, 2025

Study contacts

Anna Gold
Contact
info@acandis.com
+49 7231 155000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion